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3Abstract (224/250 words)
Background: Atopic eczema onset is described primarily in early childhood; the frequencyand characteristics of adult-onset disease remain controversial.
Objective: To determine the proportion of individuals who report atopic eczemasymptoms between birth and mid adulthood, and to examine demographic, immunologic,and genetic factors associated with period of symptom onset.
Methods: We conducted a longitudinal study using data from two nationallyrepresentative community-based birth cohorts from the United Kingdom: the BritishCohort Studies 1958 and 1970. Individuals were followed from birth through age 42-50.The primary outcome was the age period of self-reported atopic eczema symptom onsetbased on repeated measures of self-reported atopic eczema at each survey wave.
Results: The annual period prevalence of atopic eczema ranged from 5-15% in two cohortsof over 17,000 participants each followed from birth through mid-age. There was no cleartrend in prevalence by age, and among adults reporting active atopic eczema during a givenyear, only 38% had symptom onset reported in childhood. When compared withindividuals whose eczema started in childhood, those with adult-onset disease were morelikely to be women, from Scotland or Northern England, of lower childhood socio-economicgroup, smokers in adulthood, and less likely to have a history of asthma. In a sub-analysisusing data from the 1958 cohort only, genetic mutations previously associated with atopiceczema, including filaggrin null mutations, and allergen-specific IgE were more commonamong those with childhood-onset disease.
Conclusion: Rates of self-reported atopic eczema remain high after childhood, and adult-onset atopic eczema has different risk factor associations than childhood-onset eczema.
Clinical Implication: Adult-onset eczema is common and may be less likely to presentwith other atopic disease.
4Capsule Summary (29/ 30 words): In two nationally representative birth cohorts followedthrough mid-life, adult-onset eczema was most common, and the strength of associationwith demographic, immunologic and genetic factors differed from childhood-onset disease.Key words: atopic eczema, atopic dermatitis, natural history, epidemiologyAbbreviations:BCS: British Cohort StudyCI: Confidence intervalOR: Odds RatioUK: United Kingdom
5IntroductionAtopic eczema (also known as atopic dermatitis or just eczema) is the leading cause of skin-related disability,(1) but most epidemiological research has focused only on incidence earlyin life or patterns of disease in childhood.(2) Recent data suggest that atopic eczema is alsocommon among adults, but whether these trends are due to increasing persistence ofdisease or new-onset disease later in life is unclear.(3-5) Atopic eczema is known to waxand wane over time, yet there are limited longitudinal data on patterns of disease activityover the life course. Cross-sectional studies have reported proportions of adult-onsetatopic eczema ranging from 13-60%.(6-15) The validity of these estimates have beenquestioned because of the potential for recall bias (adults may not accurately recallwhether they had eczema as children) or the possibility that disease expression inadulthood is due to migration from low to high prevalence climates.(16) In addition,studies of dermatology clinic populations suggest that there may be important genetic andphenotypic differences in adult-onset disease, but these may not be representative of thegeneral population and are controversial for the reasons stated above. Data frompopulation-based longitudinal birth cohorts are needed to understand the patterns andpredictors of atopic eczema presentation across the life course.It is important to understand the epidemiology of adult-onset atopic eczema for a numberof reasons. First, since most diagnostic criteria specify that disease begins early inchildhood, patients and providers may feel uncertain of the diagnosis in adults with newonset disease. While additional testing is often appropriate to rule out differentialdiagnoses,(17) if many adults don’t meet the diagnostic criteria developed for children,they may be subject to anxiety about the lack of a clear diagnosis, excessive testing, andlimited access to new treatment options.(18) Second, if risk factors for adult-onset atopiceczema differ, this raises the possibility of a different subtype of atopic eczema and couldhelp to elucidate differences in disease pathophysiology and drivers of disease activity.Finally, understanding if childhood-onset and adult-onset atopic eczema differ is importantfor refining preventative and treatment strategies. The latter is particularly timely becausemany new small molecules and biologic agents are currently under development andclinical testing for atopic eczema.(18)Using two large cohorts followed from birth for 4-5 decades that are representative of thegeneral UK population, we sought to determine the proportion of individuals who developsymptoms of self-reported atopic eczema in childhood and adulthood, and examine factorsassociated with period of onset.
6MethodsWe performed a longitudinal cohort study using data from the 1958 and 1970 BritishCohort Studies (BCS 1958 and BCS70), which are ongoing, multidisciplinary studies thatinclude 17,196 and 17,415 babies born in Great Britain during one week in March 1958and March 1970, respectively.(19, 20) There have been 8-9 subsequent waves of follow upin each cohort at approximately 5-10 year intervals (Figure 1). In the 1958 study, waves atages 33, 46, and 55 did not include data on atopic eczema and thus were not included in theanalysis. Additional information on response patterns in both cohorts has been reportedelsewhere.(21, 22)
OutcomesThe primary outcome was parental or self-reported period prevalence of atopic eczema,based on a standardized question asking about “eczema” during or prior to the past year orsince the last survey at each wave of follow up (Supplemental Table 1). In descriptiveanalyses, this measure coincided well with standardized clinical exams among children inthe 1958 birth cohort,(23, 24) and a similar question has been shown to have highsensitivity and specificity for physician-diagnosed atopic eczema in US children andadults.(25) We categorized individuals who reported atopic eczema into two groups: thosewhose first report of atopic eczema occurred in childhood (positive parental report during
or prior to last year at age 5-7 and/or 10-11), and those with adult-onset atopic eczema(first report of atopic eczema at age 23+). For the primary analysis, we did not includeatopic eczema data from age 16, because it is considered a transitional period betweenpediatric and adult care in the UK, and the 1958 cohort only asked about annual periodprevalence (rather than period and lifetime prevalence at that age). In sensitivity analyses,data from age 16 were included.
CovariatesAdditional covariates were chosen based on prior literature showing an association withatopic eczema.(23, 26, 27) These included sex, ethnic group, history of any breastfeeding,region of residence in childhood, region of residence in adulthood (at age 42), childhoodsmoke exposure (either parent reporting current smoking during childhood surveys),smoking in adulthood (personal report of current smoking on any of the surveys inadulthood), household size (categorized into <=3 persons and 4+ persons), in utero smokeexposure (mother reported any smoking during pregnancy), birth weight, and theRegistrar General’s designation of social class (a standard measure based on the father’shighest occupational status reported on any survey at ages 0-10/11 for childhood, and anindividuals’ own occupation at ages 23-50 for adulthood). Personal history of asthma orallergic rhinitis/hay fever was based on questions repeated at multiple ages (SupplementalTable 2). Data on parental history of asthma and hay fever was only available in the 1970cohort, and was based on either parent’s report of either condition at age 5.
Primary analysisIn both cohorts, we estimated the cumulative lifetime prevalence and the age-specificperiod prevalence. We also calculated the proportion of individuals with childhood-onset
7versus adult-onset disease among those who reported active atopic eczema in adulthood.We used multivariable logistic regression to test for differences in demographic and riskfactors between 1) childhood-onset and no atopic eczema, 2) adult-onset and no atopiceczema, and 3) childhood-onset versus adult-onset atopic eczema. After examining theregression results for consistency in each cohort separately, we conducted a meta-analysisof individual participant data, assuming fixed effects across studies and accounting for theclustering of participants within cohorts.(28)
Subgroup analysis and biospecimen dataFor the subgroup of the 1958 cohort who had biospecimen data available, we repeated theregressions including variables for the presence of any filaggrin (FLG) null mutation; and anon-FLG genetic risk score, total IgE, and allergen-specific IgE modeled as 3-levelcategorical variables derived as tertiles.At the age of 44-45 years, 5,974 individuals in the 1958 cohort were followed up with abiomedical examination and blood sampling,(29) from which a DNA collection wasestablished as a nationally representative reference panel. In blood samples collected atthis adult follow up, the total concentration of serum IgE antibodies and the presence ofspecific IgE to house dust mite, mixed grass pollen and cat fur were ascertained by Hytecenzyme immunoassay, with a detection threshold of 0.35 kU/L.(30) Four common nullmutations of the FLG gene that have been associated with risk of atopic dermatitis inEuropean populations(31, 32) were genotyped directly by LGC Genomics using KASPTMgenotyping technology. FLG null status was defined as the presence of one or more riskvariants of rs61816761 (R501X), rs150597413 (S3247X), rs558269137 (2282del4) orrs138726443 (R2447X , formerly rs386430951). An additional 29 variants outside the FLGregion were selected for inclusion in a polygenic risk score, based on previously publishedassociations with atopic dermatitis (please see supplement for additional description ofmethods and full list of references). A non-FLG genetic risk score was generated as the sumof imputed allele dosages for the risk-associated variant at each of these SNPs. Additionaldetails are provided in the supplemental methods.
Sensitivity analysesFor the primary analysis, we did not include atopic eczema data from age 16, as describedabove. In a pre-planned sensitivity analysis, we tested the impact of this decision on ourresults by including individuals who reported atopic eczema during the past year at age 16with the childhood onset group. We also examined the potential for misclassification biasby restricting the sample to those who reported having seen a physician for their eczema inthe past year, and had no history of self-reported psoriasis or contact dermatitis.
Missing dataWe explored patterns of missing data throughout follow up and found that there was bothintermittent missing survey data and attrition from the cohort. For the primary analysis,we included only individuals with at least one survey response in childhood and one surveyresponse in adulthood (Figure 1). Additionally, to explore the impact of missing data, weperformed multiple imputation in each cohort separately with iterative chained equationsto impute missing exposure, outcome, and covariate data. Thirty imputed datasets were
8generated, and the average results from repeated analyses were compared to the completecase analysis. All statistical analyses were conducted using Stata, version 14 (StataCorp,Tx).
ResultsAt birth, 17,196 individuals were recruited to the 1970 cohort and 17,415 individuals wererecruited into the 1958 cohort. There was intermittent missing data and attrition in bothcohorts over time; 56-57% of the original birth sample responded to the last wave of followup (Figure 1). Data on atopic eczema in both childhood and adulthood were available for11,886 members of the 1970 cohort and 13,143 members of the 1958 cohort; demographiccharacteristics and missing covariate data are shown in Supplemental Table 3.Consistent with international trends, atopic eczema was more common in the 1970 cohort:the cumulative lifetime prevalence of atopic eczema was 28% in the 1970 cohort and 18%in the 1958 cohort. Among those with atopic eczema at any time point, 40% and 43%reported disease for the first time in adulthood in the 1970 and 1958 cohorts, respectively.The period prevalence of atopic eczema ranged from 7-14% during any given periodchildhood and 5-12% during any given period in adulthood (Supplemental Table 1), andthere was no clear trend across ages in either cohort (Figure 2). Among those who reportedatopic eczema activity at each survey wave in adulthood, the majority (mean 62%) did nothave a report of eczema during childhood (Figure 3).The strength of association from multivariate regression models comparing individualswith childhood-onset atopic eczema and adult-onset atopic eczema to individuals withoutatopic eczema differed, as is evidenced by the results of the regression model directlycomparing those with adult-onset to childhood-onset disease (Table 2). We found thatindividuals with adult-onset were more likely to be women, from Northern geographicareas in the UK, from lower social class in childhood, and smoke during adulthood; butwere less likely to have a history of asthma (Table 2).In a sub-group analysis using data from 3,365 individuals in the 1958 cohort who werepart of the biomedical follow up at age 44-45 and had atopic eczema, genetic, IgE, andcovariate data available, we examined rates of known risk alleles for AD and both total IgEand allergen-specific IgE. We found that 21% of those with childhood-onset disease, 13%with adult-onset disease, and 10% of those without any history of atopic eczema had atleast one FLG null mutation (Table 1). Both childhood-onset and adult-onset atopic eczemawere associated with FLG null mutations, but the association was stronger for childhood-onset than adult-onset in multivariable analyses (OR 2.73, 95%CI 2.06-3.63, and OR 1.49,95%CI 1.01-2.19, respectively; Table 3). A high non-FLG genetic risk score predictedchildhood-onset atopic eczema, but there was little evidence for an association between thenon-FLG genetic risk score and adult-onset disease (OR 1.81 95% CI 1.37-2.40, and OR1.18, 95%CI 0.85-1.64, respectively; Table 3). Similarly, a high allergen-specific IgEpredicted childhood-onset atopic eczema, but there was little evidence for an associationbetween the allergen-specific IgE and adult-onset disease (OR 1.90, 95%CI 1.32-2.74, and0.86, 0.54-1.36, respectively; Table 3).
9Analyses after multiple imputation to address missing data showed similar results(Supplemental Table 4). In a sensitivity analysis using data from age 16, we found that anadditional 260 individuals would be classified as having childhood-onset disease in the1970 cohort and an additional 193 children in the 1958 cohort. The overall proportion withchildhood-onset disease remained near 60% in both cohorts, and the results of theregression analyses did not change (Supplemental Table 5). Finally, when we excludedpatients who had a history of contact dermatitis or psoriasis, or did not report seeing aphysician in the past year for their atopic eczema (Supplemental Table 6), we again foundsimilar results (Supplemental Table 7).
DiscussionUsing two large population-based cohorts followed from birth into midlife, we found theperiod prevalence of self-reported atopic eczema was 5-14%. One of the definingcharacteristics of childhood atopic eczema is early age at onset; however, the majority ofthose reporting symptoms in adulthood did not have disease onset in childhood. Whencomparing those with childhood-onset and adult-onset atopic eczema, we founddifferences in demographic characteristics, atopic comorbidities, IgE profile in adulthood,and genetic risk factors. Our findings help to address the gap in knowledge about theepidemiology of adult atopic eczema, and suggest that there may be different subtypes ofadult disease that warrant additional characterization.
Strengths and limitationsOur study is unique in that there is prospective follow up of individuals residing in the UKfrom birth through mid-age. The data come from two large community-based cohortsbroadly representative of the UK general population. Consistent with previous reports andinternational trends,(33-35) we found that the overall prevalence of atopic eczemaincreased between 1958 and 1970; but there did not appear to be a difference in trendsacross calendar year (Supplemental Figure 1). Two population-based mail surveys in theUS and Italy also found high rates of adult-onset disease (54% and 60% of the populationrespectively,(7, 36)), but have been questioned because of the possibility for poor recall ofchildhood disease or migration to new climates.(16) These biases are unlikely to affect ourestimates since individuals in our cohorts were born in the UK and followed with repeatedassessments from birth through mid-life. We likely found a lower proportion of individualswith early-onset disease because our data included a longer duration of prospective follow-up than prior studies.(37) For example, an older study using data available through age 23from the 1958 BCS concluded that of the 870 cases by the age of 16 years, 66% had age ofonset by the age of 7 years.(38) By comparison, using the same initial data, now withextended follow-up through age 50, we found only 41% had onset of symptoms by age 7.Longitudinal studies of asthma have similarly found higher rates of late-onset andrecurrent disease with longer periods of follow up.(39, 40)A limitation of our study is that our outcome of atopic eczema was based on parental- orself-report and it is likely that some patients were misclassified. Misclassification couldinclude other forms of eczema, including stasis dermatitis and irritant contact dermatitis in
10
adults. Nearly all of the population-based epidemiologic literature on atopic eczema hasrelied on self-reported assessment of disease, and prior studies have shown that self-reportperforms reasonably well, though better in children than adults (positive predictive valuefor physician-diagnosis was 0.87, 95% CI 0.78-0.96 in children and 0.76, 95% CI: 0.64-0.85in adults in a multi-center US study).(25) Additional analyses to examine the potential formisclassification including restricting our sample to those who reported having seen aphysician for their atopic eczema and never reported contact dermatitis and psoriasis weresimilar to the primary regression results (Supplemental Table 7). While these results donot rule out the potential for misclassification bias, they suggest that the magnitude of biasis likely to be small. Furthermore, as described in more detail below, our findings onfilaggrin mutations, IgE, and demographic factors are similar to smaller studies of clinicalpopulations with physician-diagnosed atopic eczema. (15, 16, 41, 42)An additional limitation of our study is that surveys were fielded at multi-year intervalsand we cannot rule out the possibility that atopic eczema may be underreported. Forexample, some parents may not recall a history of early or mild atopic eczema when askedat age 5-7 of their child’s life; however, the recall is likely to be superior to surveys of adultsasked about their own early childhood disease decades later.(43) Similarly, many of theadult surveys only asked about atopic eczema during the past year (as shown insupplemental table 1), and our results may underestimate adult-onset atopic eczema.Detailed phenotypic assessments of participants to detect atopic eczema at frequentintervals would be desirable, but they are impractical in large population-based cohortsfollowed for over 40 years.Finally, as with any long-term study, the data are limited by attrition over time. Priorresearch has shown that in the 1970 cohort, there is a weak predictive effect of sex andsocioeconomic status on response: men from lower social backgrounds with less educatedparents are less likely to respond, which has previously been described in detail.(44)Because the cohort was not explicitly designed to study atopic disease, it is unlikely thatattrition was differential by atopic eczema status. Nonetheless, to address missing dataissues, we performed multiple imputation and found results that were consistent with thecomplete-case analysis.
Implications for research and clinical practiceOur results highlight the need for additional research to better characterize adult eczemaand understand whether the pathophysiology differs by age of onset. Atopic eczema isknown to have a multifactorial etiology, and we found genetic, immunologic, demographic,and risk factor differences between childhood onset and adult onset disease. Only a fewother smaller studies have explicitly addressed age-associated differences in atopiceczema, and their findings are largely consistent with our results. Studies fromdermatology clinic populations in Germany and the US also found that those with self-reported adult-onset disease were more likely to be female(42) and less likely to have apersonal or family history of atopic disease(41, 42) elevated IgE levels;(41, 45) or filaggrinmutations,(46, 47) but did not find differences by smoking or socioeconomic status.(42) Incontrast, a small case-control study from Taiwan found both current and ever smokingwere strong independent risk factors for adult-onset disease,(48) and a recent meta-
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analysis found high rates of smoking in adults with AD overall, but did not differentiate byage of onset.(49)Atopic eczema is considered to be a clinical diagnosis, and the most widely used diagnosticcriteria (the Hanifin and Rajka criteria, the UK Working Party criteria refinement of theHanifin and Rajka criteria, and the American Academy of Dermatology criteria) all includeearly age at onset and history of atopy.(50) Clinicians evaluating adults with a potentialdiagnosis of atopic eczema should recognize that the majority of patients may not havesymptom onset in childhood. Moreover, while individuals with adult-onset disease have ahigher probability of having a history of other atopic disease than individuals withoutatopic eczema, asthma is only present in about 1/3 and allergic rhinitis in about ½ of atopiceczema patients (Table 1). Diagnostic criteria were developed based on expert opinionamong dermatologists whose clinical experience may not reflect the distribution of diseasein the general population, and none have been validated in a population-based study ofadults.(51) Our data highlight the need to better understand what is adult “atopic” eczemaand to refine diagnostic criteria for use in the general adult population. In the meantime,clinical trials of adult “atopic” eczema should describe the method by which physiciansmade the diagnosis (if any) and whether validated diagnostic criteria were used that wouldpermit exploration or study heterogeneity and subgroup analyses in future meta-analyses.”
TerminologyWe choose to use the term atopic eczema based on a call for consistency in theliterature.(52) There are regional variations in terminology; in the UK, the term ‘eczema’ isconsidered more precise than ‘dermatitis’; while in the US, the term ‘atopic dermatitis’ isusually preferred.(52) In either case, use of the term ‘atopic’ has been debated because,even among children, not all disease is associated with elevated IgE levels or comorbidatopic conditions including asthma or rhinitis. Indeed, previous research has suggestedthat the majority of what is called atopic eczema is not atopic at a population-level.(53) Ourfindings that adult-onset disease was associated with lower rates of IgE and asthma furthercall into question the use of the term ‘atopic’ in adult disease; nonetheless, we havecontinued to use this terminology for consistency and clarity. Future studies may uncoversubtypes of adult-onset disease that require new terminology.
ConclusionWe found that self-reported adult-onset atopic eczema is common among two community-based British cohorts. Differences in genetic, demographic, and immunologic profilesbetween childhood-onset and adult-onset disease suggest there may be different subtypesof atopic eczema and emphasize the need for better characterization of adult-onset diseaseand validation of diagnostic tools in this population. These data are particularly timelybecause dozens of new treatments are under development and clinical testing for AD,(18)and trial populations selected on the basis of early onset disease are unlikely to berepresentative of the general population of adults.
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Figure 1. Flowchart of ages at which atopic eczema activity was assessed
Legend: Percentages represent proportion of original sample assessed at each age. Red shadingindicates ages used to define childhood-onset atopic eczema and blue shading indicates ages usedto define adult-onset atopic eczema. Data from age 16 was included with childhood-onset disease ina sensitivity analysis.
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Figure 2. Atopic eczema period prevalence and cumulative lifetime prevalence by age and bycohort
Legend: *Prevalence from age 0-5 for 1970 cohort and age 0-7 for 1958 cohort; bars represent 95%confidence intervals.
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Figure 3. Proportion of individuals with symptom onset in adulthood among those withactive atopic eczema at each survey wave in adulthood
Note: Age periods with * are from the 1958 cohort; the remainder are from the 1970 cohort. Childhood-onset diseasedefined as first report at age 0-11; adult-onset disease defined as first report after age 22-23
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Table 1. Patient characteristics by AE and period of onset1970 1958No AEN=8611 Any AEN=3275(28% of cohort) No AEN=10825 Any AEN=2318(18% of cohort)Childhood-onsetN=1972(60% of thosewith AE) Adult-onsetN=1303(40% of thosewith AE) Childhood-onsetN=1313(57% of thosewith AE) Adult-onsetN=1005(43% of thosewith AE)N (%) N (%)SexMale 4406 (51.2) 996 (50.5) 467 (35.8) 5594 (51.7) 663 (50.5) 383 (38.1)Female 4205 (48.8) 976 (49.5) 836 (64.2) 5231 (48.3) 650 (49.5) 622 (61.9)EthnicityEuropean, Caucasian 7164 (96.3) 1709 (96.8) 1071 (96.5) 8749 (99.0) 1147 (98.7) 822 (98.9)Other 272 (3.7) 56 (3.2) 39 (3.5) 88 (1.0) 15 (1.3) 9 (1.1)Region of residence inchildhoodSouthern England 2552 (33.4) 725 (40.3) 418 (36.5) 3193 (29.5) 431 (32.8) 311 (30.9)Central England 2112 (27.6) 487 (27.0) 316 (27.6) 3224 (29.8) 433 (33.0) 303 (30.1)Northern England 2988 (39.0) 589 (32.7) 411 (35.9) 4408 (40.7) 449 (34.2) 391 (38.9)Region of residence atage 42Southern England 2283 (37.0) 636 (43.3) 402 (38.5) 3136 (37.1) 429 (40.5) 365 (39.9)Central England 1671 (27.1) 404 (27.5) 290 (27.8) 2199 (26.0) 302 (28.5) 261 (28.5)Northern England 2215 (35.9) 429 (29.2) 351 (33.7) 3115 (36.9) 327 (30.9) 289 (31.6)Social class in childhoodI/II 3049 (35.4) 891 (45.2) 489 (37.6) 3072 (28.5) 455 (34.7) 306 (30.5)IIIa/b 4905 (57.0) 974 (49.4) 719 (55.2) 6597 (61.2) 749 (57.1) 603 (60.2)IV/V 648 (7.5) 106 (5.4) 94 (7.2) 1104 (10.2) 107 (8.2) 93 (9.3)Social class in adulthoodI/II 4326 (53.2) 1156 (61.1) 720 (57.4) 4573 (43.7) 607 (47.6) 482 (49.6)
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IIIa/b 3003 (36.9) 612 (32.3) 454 (36.2) 4671 (44.7) 536 (42.1) 402 (41.4)IV/V 801 (9.9) 125 (6.6) 80 (6.4) 1212 (11.6) 131 (10.3) 87 (9.0)Household size<=3 persons 821 (10.7) 183 (10.1) 121 (10.6) 857 (8.9) 115 (9.3) 75 (8.4)4+ persons 6845 (89.3) 1626 (89.9) 1022 (89.4) 8766 (91.1) 1119 (90.7) 821 (91.6)Smoking duringpregnancyNo 4635 (54.1) 1155 (58.8) 730 (56.2) 7096 (66.3) 910 (70.3) 669 (67.6)Any 3934 (45.9) 809 (41.2) 570 (43.8) 3600 (33.7) 384 (29.7) 320 (32.4)Childhood smokeexposureNo 2616 (34.2) 691 (38.2) 396 (34.7) 2173 (27.2) 316 (31.9) 215 (28.4)Any 5025 (65.8) 1117 (61.8) 745 (65.3) 5805 (72.8) 675 (68.1) 541 (71.6)Adult smokingNo 4647 (54.1) 1095 (55.6) 649 (49.8) 6076 (56.2) 764 (58.3) 533 (53.0)Any 3950 (45.9) 875 (44.4) 654 (50.2) 4736 (43.8) 547 (41.7) 472 (47.0)AtopyHistory of asthma 1451 (16.9) 627 (31.8) 378 (29.0) 2362 (21.8) 485 (36.9) 322 (32.0)History of allergicrhinitis/hay fever 3160 (36.7) 1090 (55.3) 684 (52.5) 3070 (28.4) 648 (49.4) 416 (41.4)Parental history ofatopy 1563 (22.3) 660 (39.3) 281 (27.1) --- ----- -----Birth weight (kg), mean(SD) 3.3 (0.5) 3.3 (0.5) 3.3 (0.5) 3.3 (0.5) 3.4 (0.5) 3.3 (0.5)BreastfeedingNo 4851 (63.7) 1020 (56.9) 687 (60.5) 3193 (32.2) 338 (26.9) 283 (30.9)Any 2766 (36.3) 773 (43.1) 449 (39.5) 6729 (67.8) 920 (73.1) 634 (69.1)Filaggrin null mutations*No --- --- --- 3689 (90.3) 446 (79.1) 337 (86.9)Any --- --- --- 398 (9.7) 118 (20.9) 51 (13.1)Non-FLG SNPs*< 25 risk alleles --- --- --- 1196 (29.3) 124 (22.0) 97 (25.0)25-28 risk alleles --- --- --- 1536 (37.6) 189 (33.5) 139 (35.8)
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> 28 risk alleles --- --- --- 1355 (33.2) 251 (44.5) 152 (39.2)Total IgE*<30kU/L --- --- --- 2157 (52.8) 239 (42.4) 184 (47.4)30-99 kU/L --- --- --- 1154 (28.2) 176 (31.2) 119 (30.7)>=100kU/L --- --- --- 776 (19.0) 149 (26.4) 85 (21.9)Allergen-specific IgE*<0.35kU/L --- --- --- 3007 (73.6) 321 (56.9) 260 (67.0)0.35-3.5 kU/L --- --- --- 369 (9.0) 51 (9.0) 37 (9.5)
Notes: *Data only available for a subset of the 1958 cohort (N=5,039)
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Table 2. Multivariable regression results (complete case analysis)Childhood-onsetvs no AEN= 17,373 Adult-onsetvs no AEN=12,956 Adult-onsetvs childhood-onset AEN=12,956Odds Ratio (95% CI) p-valueSexMale Reference Reference ReferenceFemale 1.04 (0.95, 1.13) 1.75 (1.56, 1.98) 1.66 (1.44, 1.92) <0.001EthnicityEuropean, Caucasian Reference Reference ReferenceOther 0.86 (0.65, 1.15) 1.07 (0.73, 1.57) 1.23 (0.77, 1.97) 0.391Region of early childhood residenceSouthern England Reference Reference ReferenceCentral England/Wales 0.91 (0.82, 1.02) 0.88 (0.73, 1.08) 0.95 (0.75, 1.20) 0.651N. England/Scotland 0.77 (0.70, 0.86) 1.03 (0.83, 1.29) 1.31 (1.01, 1.71) 0.045Region of residence at age 42Southern England ----- Reference ReferenceCentral England/Wales ----- 1.17 (0.96, 1.42) 1.14 (0.90, 1.43) 0.281N. England/Scotland ----- 0.87 (0.70, 1.09) 0.92 (0.71, 1.20) 0.551Highest social class in childhood*I/II Reference Reference ReferenceIII 0.80 (0.73, 0.88) 1.00 (0.88, 1.14) 1.23 (1.05, 1.43) 0.009IV/V 0.70 (0.58, 0.85) 0.99 (0.77, 1.26) 1.38 (1.01, 1.89) 0.044Highest social class in adulthood*I/II ----- Reference ReferenceIII ----- 0.92 (0.81, 1.04) 1.00 (0.86, 1.17) 0.956IV/V ----- 0.75 (0.58, 0.96) 0.90 (0.66, 1.22) 0.489Household size in early childhood<=3 persons Reference Reference Reference4+ persons 1.01 (0.87, 1.17) 1.08 (0.88, 1.31) 1.10 (0.87, 1.40) 0.439In utero smoke exposureNo Reference Reference ReferenceAny 0.93 (0.84, 1.03) 0.94 (0.82, 1.07) 0.99 (0.84, 1.16) 0.915Childhood smoke exposureNo Reference Reference ReferenceAny 0.93 (0.85, 1.03) 1.02 (0.89, 1.16) 1.07 (0.91, 1.26) 0.400Adulthood smokingNo ----- Reference ReferenceAny ----- 1.26 (1.13, 1.42) 1.20 (1.04, 1.38) 0.013Asthma
23
No Reference Reference ReferenceAny 1.85 (1.68, 2.04) 1.45 (1.27, 1.66) 0.79 (0.68, 0.93) 0.004Allergic rhinitis/hay feverNo Reference Reference ReferenceAny 1.81 (1.65, 1.98) 1.59 (1.41, 1.80) 0.90 (0.77, 1.04) 0.141Birth weightPer kg increase 1.09 (1.00, 1.19) 1.01 (0.90, 1.13) 0.90 (0.79, 1.04) 0.156BreastfeedingNo Reference Reference ReferenceAny 1.18 (1.07, 1.29) 1.11 (0.98, 1.26) 0.94 (0.81, 1.09) 0.411
Notes: *Registrar General’s social class: I Professional, II Managerial and technical; III Skilled; IVPartly-skilled; V Unskilled.
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Table 3. Multivariable regression results from sub-analysis with genetic data from the1958 birth cohort* Child-onset vsno AEN=3,444 Adult-onset vsno AEN=3,365 Adult-onset vschild-onset AEN=3,365Odds Ratio (95% CI) p-valueFilaggrin null mutationsNo Reference Reference ReferenceAny 2.73 (2.06, 3.63) 1.49 (1.01, 2.19) 0.54 (0.35, 0.83) 0.006Non-FLG SNPs< 25 risk alleles Reference Reference Reference25-28 risk alleles 1.17 (0.87, 1.58) 1.07 (0.77, 1.48) 0.87 (0.57, 1.32) 0.507> 28 risk alleles 1.81 (1.37, 2.40) 1.18 (0.85, 1.64) 0.64 (0.43, 0.97) 0.036Total IgE<30kU/L Reference Reference Reference30-99 kU/L 1.14 (0.83, 1.56) 1.08 (0.76, 1.54) 0.96 (0.61, 1.51) 0.866>=100kU/L 0.93 (0.63, 1.38) 1.08 (0.68, 1.71) 1.22 (0.68, 2.17) 0.503Allergen-specific IgE<0.35kU/L Reference Reference Reference0.35-3.5 kU/L 1.09 (0.69, 1.71) 1.05 (0.63, 1.74) 0.94 (0.49, 1.78) 0.846>=3.5kU/L 1.90 (1.32, 2.74) 0.86 (0.54, 1.36) 0.44 (0.25, 0.77) 0.004SexMale Reference Reference ReferenceFemale 0.98 (0.79, 1.22) 1.67 (1.27, 2.19) 1.71 (1.23, 2.39) 0.002Region of early childhood residenceSouthern England Reference Reference ReferenceCentral England/Wales 0.84 (0.64, 1.10) 1.03 (0.68, 1.57) 1.17 (0.71, 1.94) 0.535N. England/Scotland 0.65 (0.49, 0.85) 1.30 (0.81, 2.07) 1.64 (0.92, 2.93) 0.094Region of residence at age 42Southern England ----- Reference ReferenceCentral England/Wales ----- 1.15 (0.77, 1.70) 1.16 (0.72, 1.87) 0.550N. England/Scotland ----- 0.67 (0.42, 1.08) 0.85 (0.47, 1.53) 0.585Social class in childhood**I/II Reference Reference ReferenceIIIa/b 0.99 (0.78, 1.25) 1.05 (0.78, 1.41) 1.08 (0.76, 1.55) 0.662IV/V 0.79 (0.50, 1.26) 1.29 (0.79, 2.09) 1.61 (0.85, 3.06) 0.142Highest social class in adulthood**I/II ----- Reference ReferenceIII ----- 0.85 (0.64, 1.13) 0.77 (0.54, 1.08) 0.131IV/V ----- 0.74 (0.44, 1.22) 0.75 (0.40, 1.41) 0.369
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Household size in early childhood<=3 persons Reference Reference Reference4+ persons 0.87 (0.59, 1.27) 1.14 (0.69, 1.89) 1.30 (0.71, 2.38) 0.388In utero smoke exposureNo Reference Reference ReferenceAny 0.92 (0.71, 1.19) 0.99 (0.73, 1.35) 1.08 (0.74, 1.58) 0.697Childhood smoke exposureNo Reference Reference ReferenceAny 0.93 (0.73, 1.19) 0.93 (0.69, 1.26) 0.98 (0.68, 1.42) 0.910Adulthood smokingNo ----- Reference ReferenceAny ----- 1.01 (0.77, 1.33) 0.94 (0.68, 1.32) 0.739AsthmaNo Reference Reference ReferenceAny 1.53 (1.21, 1.94) 1.38 (1.03, 1.85) 0.88 (0.62, 1.25) 0.482Allergic rhinitis/hay feverNo Reference Reference ReferenceAny 1.62 (1.26, 2.07) 1.54 (1.14, 2.06) 0.95 (0.66, 1.36) 0.761Birth weightPer kg increase 0.98 (0.79, 1.21) 1.03 (0.80, 1.34) 1.03 (0.75, 1.41) 0.870BreastfeedingNo Reference Reference ReferenceAny 1.18 (0.91, 1.51) 0.97 (0.73, 1.30) 0.81 (0.57, 1.17) 0.264Notes: *Does not include data from survey at age 50. **Registrar General’s social class: IProfessional, II Managerial and technical; III Skilled; IV Partly-skilled; V Unskilled.
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Supplemental tables and figures
Supplemental Table 1. Summary of atopic eczema variablesAge Format Question Numberwhoansweredquestion
Number whorespondedpositively
1970 CohortAge 5 Parent interview Eczema during or prior to past year? 12,183 1,495 12%Age 10 Interview & exam Eczema during or prior to past year?Eczema during past year? 12,38912,373 1,795887 14%7%Age 16* Interview & exam Eczema during past year? 8,900 668 8%Age 26 Postal questionnaire Eczema during past year? 8,333 963 12%Age 30 Computer interview Eczema during past year? 10,394 978 9%Age 34 Computer interview Eczema since last survey? 8,954 662 7%Age 38 Telephone interview Eczema currently? 8,204 604 7%Age 42 Computer interview Eczema since last survey? 9,093 566 6%
1958 CohortAge 7 Interview and exam Eczema during or prior to past year? 14,030 1,100 8%Age 11 Interview and exam Eczema during or prior to past year?Eczema during past year? 12,99112,983 917652 7%5%Age 16* Interview and exam Eczema in the past year? 13,701 470 3%Age 23 Interview Eczema in the past year? 11,838 634 5%Age 42 Computer Interview Eczema in the past year? 10,788 812 8%Age 50 Postal questionnaire Eczema currently? 9,250 442 5%Notes: *Data used in sensitivity analysis
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Supplemental Table 2. Summary of asthma and hay fever variables
Age Format Question
Numberwhoansweredquestion Number whorespondedpositively
Asthma - 1970 CohortAge 10 Exam Asthma during or prior to last year? 11,984 605 5%Age 16 Interview & exam Asthma during or prior to last year? 5,251 649 12%Age 26 Postal questionnaire Asthma during or prior to last year? 8,333 1,022 12%Age 30 Computer interview Ever had asthma? 10,395 1,424 14%Age 34 Computer interview Asthma during or prior to last year? 8,954 936 10%Age 38 Telephone interview Asthma currently? 8,204 853 10%Age 42 Computer interview Asthma since last survey? 9,091 798 9%
Asthma - 1958 CohortAge 7 Interview and exam Ever had asthma? 14,036 431 3%Age 11 Parent interview Ever had asthma or wheezy bronchitis? 12,863 1,596 12%Age 16 Parent interview Ever had asthma or wheezy bronchitis? 10,744 1,257 12%Age 23 Interview Asthma, bronchitis since age 16? 11,877 514 4%Age 33 Interview Ever been told has asthma? 10,794 972 9%Age 42 Computer interview Ever had asthma? 10,799 1,199 11%Age 50 Questionnaire Asthma or wheezy bronchitis currently? 9,250 903 10%
Rhinitis/hay fever - 1970 CohortAge 5 Parent interview Hay fever during or prior to last year? 12,149 536 4%Age 10 Interview & Exam Hay fever during or prior to last year? 12,338 1,663 13%Age 16 Interview & exam Hay fever during or prior to last year? 8,928 2,285 26%Age 26 Postal questionnaire Hay fever during or prior to last year? 8,333 2,478 30%Age 30 Computer interview Ever had hay fever? 10,395 2,694 26%Age 34 Computer interview Hay fever since last survey? 8,954 1,984 22%Age 38 Telephone interview Hay fever currently? 8,204 1,640 20%Age 42 Computer interview Hay fever since last survey? 9,091 1,965 22%
Rhinitis/ Hay fever - 1958 CohortAge 7 Parent interview Hay fever or sneezing attacks ever? 14,020 774 6%Age 11 Parent interview Hay fever during the last year? 12,934 1,048 8%Age 16 Parent interview Hay fever during the last year? 10,553 1,279 12%Age 23 Interview Hay fever during the last year? 11,825 1,960 17%Age 33 Interview Ever suffered from hay fever 10,772 2,204 20%Age 42 Computer interview Ever had hay fever? 10,799 2,223 21%Age 50 Questionnaire Hay fever currently? 9,250 1,255 14%
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Supplemental Table 3: Cohort characteristics and missing data1970 CohortN (%) 1958 CohortN (%)Overall N 17196 17415SexMale 8908 (51.8) 9001 (51.7)Female 8280 (48.2) 8411 (48.3)Missing 8 (0.01) 3 (0.02)EthnicityEuropean, Caucasian 11809 (68.7) 12019 (69.0)African 154 (0.9) 98 (0.6)Indian-Pakastani 178 (1.0) 32 (0.2)Other 179 (1.0) 30 (0.2)Missing 4876 (28.4) 5236 (30.1)Region of residence in childhoodSouthern England 4430 (25.8) 5365 (30.8)Central England 3465 (20.2) 5103 (29.3)Northern England 4812 (28.0) 6947 (39.9)Missing 4489 (26.1) 0 (0.0)Region of residence at age 42Southern England 3532 (20.5) 4093 (23.5)Central England 2460 (14.3) 2859 (16.4)Northern England 3122 (18.2) 3878 (22.3)Missing 8082 (47.0) 6585 (37.8)BreastfeedingNo 7975 (46.4) 4435 (25.5)Any 4663 (27.1) 9587 (55.1)Missing 4558 (26.5) 3393 (19.5)Childhood smoke exposureaNo 4347 (25.3) 2993 (17.2)Any 8351 (48.6) 7953 (45.7)Missing 4498 (26.2) 6469 (37.1)Adulthood smokingNo 6746 (39.2) 7680 (44.1)Any 5784 (33.6) 6004 (34.5)Missing 4666 (27.1) 3731 (21.4)Smoking during pregnancyNo 9210 (53.6) 11407 (65.5)Any 7899 (45.9) 5783 (33.2)Missing 87 (0.5) 225 (1.3)Household sizeb<=3 persons 1340 (7.8) 1213 (7.0)
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4+ persons 11395 (66.3) 12357 (71.0)Missing 4461 (25.9) 3845 (22.1)Atopic historyPersonal history of asthma 2726 (15.9) 3553 (20.4)Missing 2911 (16.9) 1527 (8.8)Personal history of allergicrhinitis/hay fever 5556 (32.3) 4511 (25.9)Missing 2241 (13.0) 1533 (8.8)Parental history of asthma orallergic rhinitis/hay fever 2961 (17.2) N/AMissing 5584 (32.5) N/ASocial class in childhoodI/II 5756 (33.5) 4737 (27.2)IIIa/b 9592 (55.8) 10459 (60.1)IV/V 1750 (10.2) 1990 (11.4)Missing 98 (0.6) 229 (1.3)Social class in adulthoodI/II 6517 (37.9) 5864 (33.7)IIIa/b 4300 (25.0) 5834 (33.5)IV/V 1068 (6.2) 1520 (8.7)Missing 5311 (30.9) 4197 (24.1)Birth weight (kg), mean (SD) 3.3 (0.6) 3.3 (0.6)Missing 35 (0.2) 634 (3.6)a At age 5 in the 1970 cohort and age 16 in the 1958 cohortb At age 5 in the 1970 cohort and age 7 in the 1958 cohort
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Supplemental Table 4. Multivariable regression results for each cohort individually and imputation results1970 1958Complete case Imputation Complete case ImputationChild-onset vsno AE Adult-onset vsno AE Adult-onset vschild-onset AE Adult-onset vschild-onset AE Child-onset vsno AE Adult-onset vsno AE Adult-onset vschild-onset AE Adult-onset vschild-onset AEN=9310 N=6600 N=6600 N=17196 N=7245 N=5800 N=5800 N=17415Odds Ratio (95% CI) Odds Ratio (95% CI)SexMale Reference Reference Reference Reference Reference Reference Reference ReferenceFemale 1.04(0.93, 1.16) 1.84(1.56, 2.15) 1.79(1.48, 2.16) 1.47(1.27, 1.70) 1.04(0.89, 1.20) 1.67(1.38, 2.02) 1.54(1.21, 1.96) 1.52(1.30, 1.79)EthnicityEuropean,Caucasian Reference Reference Reference Reference Reference Reference Reference ReferenceOther 0.92(0.67, 1.26) 0.96(0.62, 1.50) 1.00(0.58, 1.70) 1.17(0.81, 1.69) 1.01(0.42, 2.43) 1.44(0.49, 4.22) 1.07(0.28, 4.04) 1.04(0.49, 2.22)Region of early childhood residenceSouthern England Reference Reference Reference Reference Reference Reference Reference ReferenceCentral England 0.87(0.75, 1.00) 0.86(0.65, 1.14) 0.95(0.69, 1.32) 1.01(0.79, 1.29) 1.02(0.85, 1.23) 0.94(0.70, 1.27) 0.93(0.65, 1.34) 1.01(0.80, 1.26)Northern England 0.79(0.69, 0.90) 0.91(0.67, 1.24) 1.07(0.74, 1.54) 1.04(0.77, 1.41) 0.79(0.65, 0.95) 1.27(0.91, 1.76) 1.74(1.14, 2.66) 1.22(0.96, 1.55)Region of early adulthood residenceSouthern England ----- Reference Reference Reference ----- Reference Reference ReferenceCentral England ----- 1.19(0.90, 1.57) 1.13(0.82, 1.56) 1.12(0.86, 1.45) ----- 1.16(0.87, 1.54) 1.15(0.80, 1.64) 1.00(0.79, 1.26)Northern England ----- 1.05(0.77, 1.44) 1.14(0.79, 1.65) 1.17(0.86, 1.60) ----- 0.66(0.48, 0.92) 0.67(0.44, 1.02) 0.87(0.67, 1.13)Social class in childhoodI/II Reference Reference Reference Reference Reference Reference Reference ReferenceIIIa/b 0.81(0.72, 0.91) 0.99(0.84, 1.17) 1.23(1.01, 1.50) 1.20(1.04, 1.38) 0.89(0.75, 1.04) 1.02(0.83, 1.25) 1.10(0.85, 1.42) 1.18(0.99, 1.40)IV/V 0.78(0.60, 1.02) 1.00(0.71, 1.43) 1.35(0.87, 2.09) 1.35(1.00, 1.81) 0.74(0.54, 1.01) 0.99(0.68, 1.43) 1.19(0.74, 1.93) 1.36(1.00, 1.87)
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Social class in adulthoodI/II ----- Reference Reference Reference ----- Reference Reference ReferenceIIIa/b ----- 1.00(0.85, 1.19) 1.06(0.86, 1.29) 1.16(1.00, 1.36) ----- 0.86(0.71, 1.05) 0.97(0.76, 1.25) 0.95(0.80, 1.13)IV/V ----- 0.67(0.47, 0.96) 0.90(0.58, 1.38) 1.07(0.79, 1.45) ----- 0.86(0.59, 1.27) 0.88(0.54, 1.44) 0.87(0.65, 1.17)Household size in early childhood<=3 persons Reference Reference Reference Reference Reference Reference Reference Reference4+ persons 1.06(0.88, 1.27) 1.03(0.80, 1.31) 0.97(0.72, 1.30) 1.02(0.81, 1.28) 0.82(0.63, 1.06) 1.16(0.81, 1.66) 1.50(0.98, 2.30) 1.21(0.92, 1.58)In utero smoke exposureNo Reference Reference Reference Reference Reference Reference Reference ReferenceAny 0.99(0.87, 1.12) 1.01(0.85, 1.20) 0.99(0.80, 1.21) 0.97(0.83, 1.13) 0.90(0.75, 1.07) 0.82(0.66, 1.02) 0.90(0.68, 1.19) 1.02(0.84, 1.24)Childhood smoke exposureNo Reference Reference Reference Reference Reference Reference Reference ReferenceAny 0.96(0.84, 1.09) 1.02(0.85, 1.21) 1.01(0.82, 1.25) 1.07(0.92, 1.25) 0.92(0.77, 1.09) 1.00(0.81, 1.24) 1.11(0.85, 1.45) 1.11(0.87, 1.43)Adulthood smokingNo ----- Reference Reference Reference ----- Reference Reference ReferenceAny ----- 1.35(1.16, 1.58) 1.32(1.10, 1.59) 1.22(1.06, 1.41) ----- 1.17(0.97, 1.42) 1.09(0.86, 1.39) 1.20(1.00, 1.43)Other atopic historyHistory of asthma 1.90(1.66, 2.16) 1.58(1.32, 1.89) 0.85(0.69, 1.05) 0.81(0.69, 0.96) 1.76(1.50, 2.07) 1.30(1.05, 1.60) 0.73(0.57, 0.94) 0.79(0.66, 0.95)History of allergicrhinitis/hay fever 1.55(1.38, 1.75) 1.62(1.38, 1.90) 1.06(0.87, 1.29) 0.88(0.76, 1.02) 2.02(1.73, 2.35) 1.51(1.25, 1.84) 0.78(0.61, 1.00) 0.74(0.62, 0.87)Parental history ofatopy 1.90(1.69, 2.15) 1.07(0.89, 1.27) 0.56(0.46, 0.69) 0.57(0.49, 0.66) ----- ----- ----- -----Birth weightPer kg increase 1.09(0.98, 1.21) 0.93(0.80, 1.08) 0.82(0.69, 0.99) 0.86(0.76, 0.98) 1.06(0.91, 1.23) 1.13(0.94, 1.36) 1.08(0.86, 1.37) 0.93(0.78, 1.10)Breastfeeding
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No Reference Reference Reference Reference Reference Reference Reference ReferenceAny 1.19(1.06, 1.33) 1.18(1.01, 1.39) 0.95(0.79, 1.15) 0.88(0.76, 1.02) 1.15(0.97, 1.37) 1.02(0.83, 1.26) 0.93(0.71, 1.21) 0.84(0.69, 1.02)
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Supplemental Table 5: Sensitivity analysis: Multivariable regression results showing the odds of adult-onset vs childhood-onset AEincluding data from age 16 in childhood-onset group.1970 1958Child-onsetAEN (%) Adult-onsetAEN (%) Adult-onset vschild-onset AEOR (95% CI) Child-onsetAEN (%) Adult-onsetAEN (%) Adult-onset vschild-onset AEOR (95% CI)N=2232(64% of thosewith AE) N=1246(36% of thosewith AE) N=6617 N=1506(60% ofthose withAE) N=997(40% of thosewith AE) N=5800SexMale 1079 (48.3) 459 (36.8) Reference 729 (48.4) 386 (38.7) ReferenceFemale 1153 (51.7) 787 (63.2) 1.53 (1.26, 1.84) 777 (51.6) 611 (61.3) 1.40 (1.10, 1.77)EthnicityEuropean, Caucasian 1911 (96.8) 1003 (96.4) Reference 1310 (98.8) 783 (98.9) ReferenceOther 63 (3.2) 37 (3.6) 1.01 (0.59, 1.73) 16 (1.2) 9 (1.1) 1.36 (0.36, 5.16)Region of residence inchildhoodSouthern England 800 (39.7) 389 (36.3) Reference 485 (32.2) 308 (30.9) ReferenceCentral England 559 (27.8) 293 (27.3) 0.98 (0.70, 1.36) 493 (32.7) 295 (29.6) 0.95 (0.66, 1.36)Northern England 655 (32.5) 390 (36.4) 1.21 (0.84, 1.74) 528 (35.1) 394 (39.5) 1.70 (1.12, 2.57)Region of residence inadulthoodSouthern England 711 (42.5) 382 (38.4) Reference 477 (39.3) 363 (40.0) ReferenceCentral England 473 (28.3) 272 (27.3) 1.06 (0.76, 1.46) 346 (28.5) 257 (28.3) 1.09 (0.77, 1.55)Northern England 489 (29.2) 341 (34.3) 1.04 (0.72, 1.51) 392 (32.3) 288 (31.7) 0.65 (0.44, 0.99)Social class in childhoodI/II 991 (44.4) 462 (37.2) Reference 506 (33.7) 297 (29.9) ReferenceIIIa/b 1112 (49.9) 685 (55.2) 1.19 (0.98, 1.45) 869 (57.9) 597 (60.1) 1.05 (0.82, 1.36)IV/V 127 (5.7) 95 (7.6) 1.21 (0.78, 1.86) 127 (8.5) 99 (10.0) 1.01 (0.63, 1.62)Social class in adulthoodI/II 1292 (60.5) 693 (57.8) Reference 677 (46.3) 479 (50.0) ReferenceIIIa/b 697 (32.6) 431 (35.9) 1.04 (0.85, 1.28) 625 (42.8) 396 (41.3) 0.92 (0.71, 1.17)IV/V 148 (6.9) 76 (6.3) 0.87 (0.57, 1.34) 159 (10.9) 83 (8.7) 0.79 (0.49, 1.29)
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Household size<=3 persons 209 (10.3) 111 (10.4) Reference 129 (9.2) 72 (8.5) Reference4+ persons 1813 (89.7) 959 (89.6) 1.02 (0.76, 1.37) 1269 (90.8) 780 (91.5) 1.32 (0.86, 2.01)Smoking duringpregnancyNo 1310 (59.0) 697 (56.1) Reference 1022 (68.9) 666 (68.0) ReferenceAny 912 (41.0) 545 (43.9) 1.00 (0.82, 1.24) 462 (31.1) 313 (32.0) 0.82 (0.62, 1.08)Childhood smokeexposureNo 762 (37.7) 372 (34.8) Reference 355 (30.2) 209 (28.3) ReferenceAny 1259 (62.3) 696 (65.2) 0.99 (0.80, 1.23) 821 (69.8) 529 (71.7) 1.08 (0.83, 1.41)Adulthood smokingNo 1234 (55.4) 617 (49.5) Reference 864 (57.4) 525 (52.7) ReferenceAny 995 (44.6) 629 (50.5) 1.28 (1.06, 1.54) 640 (42.6) 472 (47.3) 1.00 (0.79, 1.27)Other atopic historyPersonal history ofasthma 714 (32.0) 357 (28.7) 0.83 (0.67, 1.02) 541 (35.9) 320 (32.1) 0.82 (0.63, 1.05)Personal history ofallergic rhinitis/hayfever 1242 (55.6) 645 (51.8) 0.99 (0.82, 1.20) 752 (49.9) 408 (40.9) 0.71 (0.56, 0.90)Parental history ofasthma or allergicrhinitis/hay fever 715 (38.0) 259 (26.7) 0.58 (0.48, 0.72) ----- ----- -----Birth weight, mean (SD) 3.3 (0.5) 3.3 (0.5) 0.82 (0.68, 0.98)* 3.3 (0.5) 3.3 (0.5) 1.07 (0.85, 1.34)*BreastfeedingNo 1153 (57.5) 639 (60.1) Reference 380 (26.7) 277 (31.6) ReferenceAny 852 (42.5) 425 (39.9) 0.99 (0.82, 1.20) 1045 (73.3) 599 (68.4) 0.87 (0.67, 1.13)Notes: *For every one kg increase in birth weight
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Supplemental Table 6. Data on contact dermatitis, psoriasis, and physician-visits by cohort and age of atopic eczema (AE) onset1970 Cohort 1958 CohortNo AEN=8611 Child-onsetN=1972(60% of thosewith AE)
Adult-onsetN=1303(40% of thosewith AE) P-value* No AEN=10825
Child-onsetN=1313(57% of thosewith AE)
Adult-onsetN=1005(43% of those withAE) P-valueContact dermatitis <0.001 <0.001No 7891 (97.8) 1755 (94.0) 1153 (90.6) 8755 (97.9) 1056 (95.0) 871 (91.6)Any 175 (2.2) 112 (6.0) 119 (9.4) 188 (2.1) 56 (5.0) 80 (8.4)Psoriasis <0.001 <0.001No 7651 (97.0) 1751 (95.1) 1153 (92.5) 10374 (96.3) 1220 (93.2) 925 (92.1)Any 233 (3.0) 91 (4.9) 94 (7.5) 402 (3.7) 89 (6.8) 79 (7.9)Reported seeing aphysician in the pastyear** 0.005 0.001No N/A 242 (61.3) 287 (52.1) N/A 129 (65.8) 308 (52.3)Any N/A 153 (38.7) 264 (47.9) N/A 67 (34.2) 281 (47.7)Notes: *p-value for chi-square, **reported at age 30 in 1970 or age 42 in 1958
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Supplemental Table 7. Sensitivity analysis results restricting to a subset of individualswith lower possibility of misclassification bias (i.e. reported seeing a MD in the last yearand no history of contact dermatitis and psoriasis).Child-onset vs noAEN= 13,099 Adult-onset vs noAEN=10,796 Adult-onset vschild-onset AEN=10,796Odds Ratio (95% CI)SexMale Reference Reference ReferenceFemale 1.06 (0.96, 1.17) 2.13 (1.64, 2.76) 2.06 (1.57, 2.71)EthnicityEuropean, Caucasian Reference Reference ReferenceOther 0.74 (0.52, 1.04) 1.16 (0.53, 2.54) 1.42 (0.61, 3.28)Region of early childhood residenceSouthern England Reference Reference ReferenceCentral England/Wales 0.91 (0.81, 1.03) 0.97 (0.64, 1.47) 0.98 (0.63, 1.53)N. England/Scotland 0.75 (0.66, 0.84) 1.08 (0.68, 1.73) 1.28 (0.77, 2.10)Region of residence at age 42Southern England ----- Reference ReferenceCentral England/Wales ----- 1.26 (0.84, 1.89) 1.26 (0.82, 1.94)N. England/Scotland ----- 0.87 (0.55, 1.39) 1.00 (0.61, 1.65)Highest social class in childhood*I/II Reference Reference ReferenceIII 0.82 (0.74, 0.91) 0.94 (0.72, 1.23) 1.11 (0.83, 1.47)IV/V 0.72 (0.58, 0.90) 0.99 (0.61, 1.61) 1.32 (0.78, 2.24)Highest social class in adulthood*I/II ----- Reference ReferenceIII ----- 1.17 (0.90, 1.51) 1.26 (0.95, 1.66)IV/V ----- 1.15 (0.72, 1.81) 1.45 (0.87, 2.39)Household size in early childhood<=3 persons Reference Reference Reference4+ persons 1.04 (0.88, 1.23) 1.02 (0.68, 1.53) 0.99 (0.64, 1.54)In utero smoke exposureNo Reference Reference ReferenceAny 0.92 (0.82, 1.03) 1.01 (0.77, 1.33) 1.10 (0.83, 1.48)Childhood smoke exposureNo Reference Reference ReferenceAny 0.93 (0.83, 1.04) 1.09 (0.82, 1.46) 1.13 (0.83, 1.53)Adulthood smokingNo ----- Reference Reference
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Any ----- 1.58 (1.24, 2.01) 1.51 (1.16, 1.96)Other atopic historyAsthma 1.88 (1.69, 2.10) 1.21 (0.91, 1.60) 0.67 (0.50, 0.90)Allergic rhinitis/hay fever 1.79 (1.62, 1.98) 1.63 (1.27, 2.09) 0.92 (0.71, 1.21)Birth weightPer kg increase 1.08 (0.98, 1.19) 0.70 (0.56, 0.89) 0.63 (0.49, 0.82)BreastfeedingNo Reference Reference ReferenceAny 1.13 (1.02, 1.26) 1.13 (0.87, 1.47) 0.96 (0.73, 1.26)
Notes: *Registrar General’s social class: I Professional, II Managerial and technical; III Skilled; IVPartly-skilled; V Unskilled.
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Supplemental Figure 1. Eczema prevalence by calendar year
* Prevalence from age 0-5 for 1970 cohort and age 0-7 for 1958 cohort; bars represent 95%CIs.
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Supplemental Methods: British 1958 birth cohort biomedical examination and
genotypingTotal and specific IgEAt the age of 44-45 years, the 1958 cohort were followed up with a biomedical examinationand blood sampling [1], from which a DNA collection was established as a nationallyrepresentative reference panel. In blood samples collected at this adult follow up, the totalconcentration of serum IgE antibodies and the presence of specific IgE to house dust mite,mixed grass pollen and cat fur were ascertained by Hytec enzyme immunoassay, with adetection threshold of 0.35 kU/L. [2]Filaggrin null mutationsThe four common null mutations of the filaggrin (FLG) gene that have been associated withrisk of atopic dermatitis [3,4] were genotyped directly by LGC Genomics using KASPTMgenotyping technology. Filaggrin null status was defined as the presence of one or more riskvariants of rs61816761 (R501X), rs150597413 (S3247X), rs558269137 (2282del4) orrs138726443 (formerly rs386430951).Genome-wide typing, imputation and generation of non-FLG genetic risk scoreThree non-overlapping subsets of the DNA collection from cohort members of whiteEuropean ethnicity were genotyped by the Wellcome Trust Case-Control Consortium(WTCCC) [5]; the Type 1 Diabetes Genetics Consortium (T1DGC) [6]; and the GABRIELconsortium [7]. Genotyping was performed using the Illumina 550K array (WTCCC1 andT1DGC), the Illumina 610K array (GABRIEL) or the Illumina 1M array (WTCCC2). A set ofSNPs common to these arrays were used for imputation against the March 2012 (phase 1,version 3) release of the 1000-genomes reference haplotypes for all ancestries. Pre-imputation phasing was performed using MACH v1.0.18 and imputation was performedusing Minimac (version dated 16 November 2012).The following 29 variants outside the FLG region were selected for inclusion in a polygenicrisk score, based on previously published associations with atopic dermatitis:rs7927894_T (risk-associated variant T) (C11orf30 / 11q13.5) [8];rs6010620_G (TNFRSF6B / 20q13.33) and rs7701890_G (TMEM232 / 5q22.1) [9];rs479844_G (OVOL1 / 11q13.1), rs2164983_A (ACTL9 / 19p13.2) and rs2897442_C(KIF3A / 5q31) [10];rs13015714_G (IL1RL1-IL18RAP / 2q12), rs114764276_A (GPSM3 / 6p21.3),rs878860_C (OR10A3-NLRP10 / 11p15.4), rs6780220_C (GLB1 /3p21.33), rs12634229_C (CCDC80 / 3q13.2), rs4722404_C (CARD11/ 7p22), rs10995251_C (ZNF365 / 10q21.2) and rs16999165_A(CYP24A1-PFDN4 / 20q13) [11];rs17389644_A (IL2-IL21 / 4q27), rs12295535_T (PRR5L / 11p13), rs2041733_T(CLEC16A-DEXI / 16p13.13) and rs16948048_G (ZNF652 /17q21.32) [12];rs12153855_T (TNXB / 6p21) [13];rs7127307_T (ETS1 / 11q24.3), rs2227483_T (IL22 / 12q15); rs2143950_T(PPP2R3C / 14q13.2), rs7146581_C (TRAF3/14q32.32),rs17881320_T (STAT3 / 17q21.2), rs11657987_T (SOCS3 /17q25.3),
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rs112111458_A (CD207 / 2p13.3), rs1057258_C (INPP5D / 2q37.1),rs10214237_T (IL7R / 5p13.2) and rs6473227_C (ZBTB10 /8q21.13) [14].A non-FLG genetic risk score was generated as the sum of imputed allele dosages for therisk-associated variant at each of these SNPs.
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